Isabel L. L.
- Country
- Spain
- Department
- Oncology
Research Overview
- Evaluation of Ribociclib Combined with Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Phase III Randomized Trial
- Phase II Evaluation of Trastuzumab, Tucatinib, and Vinorelbine in HER2-Positive Non-Resectable Locally Advanced or Metastatic Breast Cancer
- Evaluation of Diarrhea-Related Discontinuations in Early-Stage HER2+/HR+ Breast Cancer with Neratinib, Loperamide, and Colesevelam Prophylaxis
Data & Insights
Has run more than one trial at 107 of 336 partner sites.
Specializations
Early Breast Cancer Treatment
This investigator specializes in the treatment of hormone receptor-positive (HR+) and HER2-negative breast cancer in early stages. Their research encompasses evaluating novel therapeutic approaches using endocrine therapy combinations for patients with high recurrence risks.
- HR+/HER2- breast cancer management
- Node-positive breast cancer treatment
- Adjuvant therapy optimization
Advanced Cancer Care
The investigator focuses on treating various advanced cancers, including BRCA-mutated cancers and metastatic conditions. Their expertise extends to multiple cancer types including ovarian, breast, pancreatic, prostate, and endometrial cancers.
- Epithelial ovarian cancer management
- Metastatic breast cancer treatment
- BRCA-mutation targeted therapies
HER2-Positive Breast Cancer
The investigator has significant expertise in treating HER2-positive breast cancer across various stages, from early to locally advanced and metastatic disease. Their work includes evaluation of novel therapeutic combinations and treatment strategies.
- Neoadjuvant therapy approaches
- Advanced HER2+ breast cancer treatment
- Targeted therapy combinations
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.